---
figid: PMC7256878__fonc-10-00788-g0007
figlink: pmc/articles/PMC7256878/figure/F7/
number: F7
caption: mTOR pathway is a regulator of iron metabolism, targeted drugs everolimus
  and temsirolimus target the mTOR pathway to treat ccRCC patients. The VHL/HIF-α
  axis, which plays a central role in the carcinogenesis of ccRCC, is the main regulator
  target of iron metabolism. Targeting drugs such as sunitinib, sorafenib, pazopanib,
  and axitinib targeted at VHL gene pathway. Inactivation of VHL increases the sensitivity
  of ccRCC to ferroptosis. IRP1 can bind to the iron reaction element of HIF-2α mRNA
  and inhibits its translation. Tempol, an IRP1-activated drug, inhibits HIF-2α and
  HIF-1α protein levels. PT2399 and PT2385 are inhibitors of HIF-2α.
pmcid: PMC7256878
papertitle: The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis
  Prediction of Clear Cell Renal Cell Carcinoma.
reftext: Yanhua Mou, et al. Front Oncol. 2020;10:788.
pmc_ranked_result_index: '34364'
pathway_score: 0.9342577
filename: fonc-10-00788-g0007.jpg
figtitle: mTOR pathway is a regulator of iron metabolism, targeted drugs everolimus
  and temsirolimus target the mTOR pathway to treat ccRCC patients
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7256878__fonc-10-00788-g0007.html
  '@type': Dataset
  description: mTOR pathway is a regulator of iron metabolism, targeted drugs everolimus
    and temsirolimus target the mTOR pathway to treat ccRCC patients. The VHL/HIF-α
    axis, which plays a central role in the carcinogenesis of ccRCC, is the main regulator
    target of iron metabolism. Targeting drugs such as sunitinib, sorafenib, pazopanib,
    and axitinib targeted at VHL gene pathway. Inactivation of VHL increases the sensitivity
    of ccRCC to ferroptosis. IRP1 can bind to the iron reaction element of HIF-2α
    mRNA and inhibits its translation. Tempol, an IRP1-activated drug, inhibits HIF-2α
    and HIF-1α protein levels. PT2399 and PT2385 are inhibitors of HIF-2α.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TBX22
  - MTOR
  - RORC
  - VHL
  - ACO1
  - TFRC
  - EPAS1
  - HIF1A
  - DFO DFX
  - DFOM DFP
  - Everolimus
  - Fe
  - Temsirolimus
  - Sunitinib
  - Sorafenib
  - pazopanib
  - Axitinib
  - VHL
genes:
- word: CPX
  symbol: CPX
  source: hgnc_prev_symbol
  hgnc_symbol: TBX22
  entrez: '50945'
- word: mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: TOR
  symbol: TOR
  source: hgnc_alias_symbol
  hgnc_symbol: RORC
  entrez: '6097'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: IRP1
  symbol: IRP1
  source: hgnc_alias_symbol
  hgnc_symbol: ACO1
  entrez: '48'
- word: TFR1
  symbol: TFR1
  source: hgnc_alias_symbol
  hgnc_symbol: TFRC
  entrez: '7037'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: HIF-2a
  symbol: HIF2A
  source: hgnc_alias_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIF-1a
  symbol: HIF1A
  source: hgnc_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
chemicals:
- word: DFO DFX
  source: MESH
  identifier: D003676
- word: DFOM DFP
  source: MESH
  identifier: D007531
- word: Everolimus
  source: MESH
  identifier: C107135
- word: Fe
  source: MESH
  identifier: D007501
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Sunitinib
  source: MESH
  identifier: C473478
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: pazopanib
  source: MESH
  identifier: C516667
- word: Axitinib
  source: MESH
  identifier: C503983
diseases:
- word: VHL
  source: MESH
  identifier: D006623
figid_alias: PMC7256878__F7
redirect_from: /figures/PMC7256878__F7
figtype: Figure
---
